Orthocell Ltd, headquartered in Perth, Australia is the home of Remplir™.
Since 2010, Orthocell has been manufacturing and exporting novel regenerative medicine products around the world. Its biological medical devices and cellular therapies are used by leading surgeons to treat musculoskeletal injuries of nerve, tendon and cartilage, and dental bone defects.
More than 70,000 patients have been treated with Orthocell products to date, with no adverse events reported, as of March 2025.
The clinical utility of every Orthocell product is underpinned by the Company's mission to improve mobility, function and quality of life - without exception.
Orthocell works with leading surgeons and centres of excellence to translate research into novel products that improve the standard of care for patients with a variety of musculoskeletal injuries.
Orthocell’s success stems from a deep understanding of tissue engineering principles, and in particular the interaction between cells and scaffolds. Orthocell products enhance the body’s natural ability to heal and promote regeneration of nerve, tendon, cartilage and dental bone defects.
Our products are carefully designed to assist surgeons - in particular, orthopedic, plastic, reconstructive and dental surgeons - to simplify procedures, save operative time and deliver consistent and predictable outcomes for their patients.
The Orthocell team is committed to expanding its suite of medical devices and is exploring new applications for both existing and future products.
Orthocell has established a quality-controlled facility at its headquarters in Perth, Western Australia. The facility is licensed by the Therapeutic Goods Administration (TGA) and certified to ISO 13485 for the manufacture of medical devices. Orthocell is equipped to manufacture, scale up and export products around the world.
Orthocell has appointed experienced US-based executives to drive the market launch and sales of Remplir.
Vice President - Sales
Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen.
Vice President - Medical Affairs
Mr Edmondson is an award-winning medical affairs professional, who excels in creating product awareness, building advocacy and implementing successful medical education programs that contribute to sales growth.
Head of Marketing
Mr Leach is a highly regarded senior marketing executive with extensive knowledge and experience in the development and commercialization of technologies for peripheral nerve regeneration and repair in the USA.
Orthocell's Medical Scientific Advisory Board is composed of highly distinguished experts in the field of peripheral nerve repair, bringing together decades of specialised experience and cutting-edge knowledge. This esteemed group includes leaders in surgical innovation, each with a proven track record of advancing the science and treatment of peripheral nerve injuries. Their collective expertise guides our efforts in developing groundbreaking therapies and ensuring the highest standards of care, positioning us at the forefront of transforming patient outcomes in nerve repair.
Orthopedic Surgeon, specialising in nerve repair
Dr Brogan is an Associate Professor of Orthopedic Surgery at Washington University in St. Louis, where he is the Associate Director of the Orthopedic Clinical Research Center, Director of Resident Research and Associate Director of the Microsurgery Fellowship. In conjunction with Dr Christopher Dy, he directs the Orthopedic Nerve Research Lab, an NIH funded lab focused on evaluating basic science and translational techniques in peripheral nerve imaging and repair.
Learn more
Orthopedic Surgeon, specialising in nerve repair
Dr Dy is a board-certified orthopedic hand surgeon with subspecialty expertise in brachial plexus and peripheral nerve injury. He graduated from the combined BS/MD program at the University of Miami, where he also obtained an MPH degree. Dr Dy completed his orthopedic surgery residency and postdoctoral research fellowship at Hospital for Special Surgery in New York City and a fellowship in hand surgery at Washington University Orthopedics.
Learn more
Orthopedic Surgeon, specialising in nerve repair
Dr O’Beirne completed a medical degree at The University of Western Australia, graduating in 1993. He completed his internship and medical training at Royal Perth Hospital and was then selected to the orthopedic training programme in 1997, which he finished in 2002. He then completed fellowships at Royal North Shore Hospital, Sydney Australia with Professor Michael Tonkin and at St Vincent’s Hospital in Melbourne Victoria with Tony Berger and Damien Ireland. He then completed observerships at the Mayo Clinic.
Learn more
- Paul Anderson
Orthocell Co-Founder and Managing Director
Orthocell (ASX:OCC) is well-positioned for significant growth and value creation for its shareholders.
Commercial-stage regenerative medicine company manufacturing and exporting best-in-class products for Nerve, Tendon, Cartilage and Dental Bone defect repair in eight major global markets
Growing international revenue and now cleared to commence commercial distribution of its flagship nerve repair product Remplir into the globally significant US$1.6 billion1 nerve repair market which is expected to provide a step change in revenue
All products manufactured by Orthocell at its quality-controlled facility in Australia, scaled for market expansion and certified to manufacture for major jurisdictions under strict quality standards
Well-funded Company with a strong balance sheet, no debt, and no royalties payable on product sales
World-class leadership team with extensive regenerative medicine and commercialization expertise
Meet the Orthocell team
1. USA nerve repair market size was estimated using referenced papers from US and OUS databases and studies